OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
Vladislav Berdunov, Steve Millen, Andrew Paramore, et al.
ClinicoEconomics and Outcomes Research (2022) Vol. Volume 14, pp. 619-633
Open Access | Times Cited: 6
Vladislav Berdunov, Steve Millen, Andrew Paramore, et al.
ClinicoEconomics and Outcomes Research (2022) Vol. Volume 14, pp. 619-633
Open Access | Times Cited: 6
Showing 6 citing articles:
Nottingham prognostic x (NPx ): a risk stratification tool in ER ‐positive HER2 ‐negative breast cancer: a validation study
Ayat G. Lashen, Michael S. Toss, Islam M. Miligy, et al.
Histopathology (2024) Vol. 85, Iss. 3, pp. 468-477
Open Access | Times Cited: 4
Ayat G. Lashen, Michael S. Toss, Islam M. Miligy, et al.
Histopathology (2024) Vol. 85, Iss. 3, pp. 468-477
Open Access | Times Cited: 4
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
Vladislav Berdunov, Gebra Cuyún Carter, Ewan Laws, et al.
ClinicoEconomics and Outcomes Research (2024) Vol. Volume 16, pp. 471-482
Open Access | Times Cited: 3
Vladislav Berdunov, Gebra Cuyún Carter, Ewan Laws, et al.
ClinicoEconomics and Outcomes Research (2024) Vol. Volume 16, pp. 471-482
Open Access | Times Cited: 3
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer
Simon Holt, Mark Verrill, Laura Pettit, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 7, pp. 1149-1156
Open Access | Times Cited: 2
Simon Holt, Mark Verrill, Laura Pettit, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 7, pp. 1149-1156
Open Access | Times Cited: 2
Socioeconomic Impact of OncotypeDX on Breast Cancer Treatment: Preliminary Results
Gianluca Vanni, Marco Materazzo, Ilaria Portarena, et al.
In Vivo (2023) Vol. 37, Iss. 6, pp. 2510-2516
Open Access | Times Cited: 2
Gianluca Vanni, Marco Materazzo, Ilaria Portarena, et al.
In Vivo (2023) Vol. 37, Iss. 6, pp. 2510-2516
Open Access | Times Cited: 2
Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer
Ke Liu, Jiayi Li, Guanqiao Li, et al.
Expert Review of Anticancer Therapy (2024), pp. 1-9
Closed Access
Ke Liu, Jiayi Li, Guanqiao Li, et al.
Expert Review of Anticancer Therapy (2024), pp. 1-9
Closed Access
Cost–Utility Analysis of Multigene Assays to Guide Treatment Decisions for Node-Negative Early Breast Cancer
Vladislav Berdunov, Gebra Cuyún-Carter, Yaneth Gil-Rojas, et al.
Oncology and Therapy (2024)
Open Access
Vladislav Berdunov, Gebra Cuyún-Carter, Yaneth Gil-Rojas, et al.
Oncology and Therapy (2024)
Open Access
